tbuckley/cabot-search huggingface dataset:
Abstract 3946: Development of selective small molecule AR-V7 inhibitors for prostate cancer treatment
Authors: CheukMan Cherie Au, Seaho Kim, Prerna Vatsa, Mohd Azrin Bin Jamalruddin, Michael Miller, Peter T. Meinke, Paraskevi Giannakakou
Journal: Cancer Research (2022)

Abstract Castration resistance prostate cancer (CRPC) is a lethal disease in which the expression of ligand-independent androgen receptor (AR) splice variants (AR-Vs) is associated with worse clinical outcomes. AR-V7 is the most prevalent variant in CRPC, it lacks the ligand binding domain and is constitutively active in the nucleus. We and others have showed that, AR-V7 expression confers resistance to the AR signaling inhibitors (abiraterone/enzalutamide) and to taxanes in vivo and in patients with metastatic CRPC. Since abiraterone/enzalutamide and taxanes represent the two most effective therapeutic modalities for men with CRPC, the development of selective AR-V7 inhibitors is a high priority, clinically unmet need. AR-V7 shares with full-length AR (AR-fl), high sequence homology, largely overlapping cistromes and gene transactivation profiles. To develop selective AR-V7 inhibitors, we sought to identify unique biological features of AR-V7, that differentiate it from AR-fl and therapeutically exploit them. Mechanistic studies showed that AR-V7 utilizes a unique nuclear import pathway, not shared by AR-fl. Using fluorescently tagged-AR-fl or AR-V7 proteins in conjunction with live cell imaging, FRAP assays and pathway inhibitors, we showed that AR-V7 exhibits fast nuclear import kinetics partially mediated by the dimerization D-box domain, independently of microtubules and importin α/β. Taken together, these data suggest that AR-V7 nuclear import mechanism is distinct providing a window of therapeutic opportunity to selectively target it. To identify AR-V7 selective inhibitors, we designed and performed a high throughput enzyme complementation screening (HTS) assay using nuclear AR-V7 as a surrogate for AR-V7 activity. We screened a chemical library of ~170K compounds and identified hit compounds inhibiting AR-V7 by proteasomal degradation. Among the degraders, we observed 2 main modes of action: I. compounds selectively degrading AR-V7 and II. compounds degrading both AR-fl and AR-V7. Ongoing efforts include medicinal chemistry for lead compound optimization and target validation experiments.In conclusion, we identified first-in-class selective AR-V7 inhibitors, with the potential to be clinically combined with existing, but mechanistically unrelated AR signaling inhibitors. Further mechanistic studies will elucidate their potential for future clinical development. Citation Format: CheukMan Cherie Au, Seaho Kim, Prerna Vatsa, Mohd Azrin Bin Jamalruddin, Michael Miller, Peter T. Meinke, Paraskevi Giannakakou. Development of selective small molecule AR-V7 inhibitors for prostate cancer treatment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3946.
Abstract 657: Impact of therapy induced APOBEC3A mutagenesis on tumor evolution in non small cell lung cancer
Authors: Hideko Isozaki, Ammal Abbasi, Naveed Nikpour, Marcello Stanzione, Ramin Sakhtemani, Susanna L. Monroe, Alice T. Shaw, Jessica J. Lin, Lecia V. Sequist, Zofia Piotrowska, Rémi Buisson, Michael S. Lawrence, Aaron N. Hata
Journal: Cancer Research (2022)

Abstract Acquired drug resistance to even the most effective anti cancer targeted therapies remains an unsolved clinical problem. Although many drivers of acquired drug resistance have been identified, the underlying molecular mechanisms shaping tumor evolution during treatment are incompletely understood. We have seen that lung cancer targeted therapies commonly used in the clinic induce the expression of cytidine deaminase APOBEC3A (A3A), leading to sustained mutagenesis in drug tolerant cancer cells persisting during therapy. Preventing therapy induced A3A mutagenesis by gene deletion delayed the emergence of drug resistance. Here, we show that therapy induced A3A mutagenesis contributes to tumor evolution in NSCLC. Whole genome sequencing revealed that resistant clones that evolved from persistent drug tolerant cells (late clones) harbored more A3A mutations compared to the parental cell population than pre existing resistant clones (early clones). In a subset of NSCLC patients who received targeted therapies, we observed A3A mutations accompanied clonal evolution during treatment. Comparison of APOBEC mutation fractions in short vs long term responders suggests that short responders with acquired resistance mechanisms that evolved from pre existing resistant clones have less accumulation of APOBEC mutations. Collectively, these findings insist that an increase in mutagenic processes drives tumor evolution during targeted therapy treatment and leads to acquired resistance. Thus, suppressing expression or enzymatic activity of A3A may represent a potential therapeutic strategy to halt the evolution of resistant clones and prevent acquired resistance to lung cancer targeted therapy. Citation Format: Hideko Isozaki, Ammal Abbasi, Naveed Nikpour, Marcello Stanzione, Ramin Sakhtemani, Susanna L. Monroe, Alice T. Shaw, Jessica J. Lin, Lecia V. Sequist, Zofia Piotrowska, Rémi Buisson, Michael S. Lawrence, Aaron N. Hata. Impact of therapy induced APOBEC3A mutagenesis on tumor evolution in non small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 657.
Abstract 5249: Efficacy and safety of apatinib in treatment of unresectablehepatocellular carcinoma: A real-world study
Authors: Jun Liu, Guangbing Li, Qiang He, Shijun Sun, Chuanlin Zhao, Chuandong Sun, Bo Zhang, Yi Cui, Yongqiang Ye, Xuting Zhi, Shiping Li, Shiping Li, Guozheng Pan, Changlin Ma, Jinhua Hu, Jun Li, Suling Wang, Yuangang Qiao, Wanhua Ren, Qi Meng
Journal: Cancer Research (2022)

Abstract Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in China. Apatinib is a small molecule TKI inhibitor. Its efficacy and safety for unresectable HCC patients have been demonstrated in randomized controlled clinical studies. However, the efficacy and safety of apatinib in real world is lacking. We are aiming to evaluate the efficacy and safety of apatinib in real world.MethodsPatients of older than 18 years with unresectable HCC confirmed by IHC (Immunohistochemistry) or CT and MR Imaging were enrolled in the study. All patients received apatinib monotherapy or combined with other treatments including TACE and chemotherapy. The enrolled patients were treated until disease progression, death, or severe intolerable toxicity, etc. The primary endpoint was overall response rate (ORR), and secondary endpoints were disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). The adverse events (AEs) were also recorded.ResultsFrom February, 2019 to May, 2020, a total of 233 patients were enrolled. Among them, 66 (28.33%) patients received apatinib monotherapy and 167 (71.67%) patients received combination therapy. Patients with a history of hepatitis accounted for 70%. 8 patients achieved complete response (CR), 64 patients achieved partial response (PR), 120 patients achieved stable disease (SD), and 41 patients had progressive disease (PD), illustrating an ORR of 30.90% and a DCR of 82.40%. Median PFS and OS were 6.93 months (95% CI, 6.19-7.68 months) and 11.36 months (95% CI, 9.96-12.77 months), respectively. The safety profile indicated that the most common drug-related adverse events were hypertension (37.90%), hand-foot-skin reaction (27.39%), fatigue (19.11%), thrombocytopenia (16.02%). Grade 3/4 treatment related AEs included thrombocytopenia (4.30%), hypertension (3.82%), neutropenia (2.73%). After symptomatic treatment, all the adverse events were treated properly, and no unexpected adverse events were observed. Conclusions In current study, apatininb showed good tolerance with acceptable toxicity and high tumor response rate that translated into promising PFS and OS in unresectable HCC patients. ChiCTR1900021822 Citation Format: Jun Liu, Guangbing Li, Qiang He, Shijun Sun, Chuanlin Zhao, Chuandong Sun, Bo Zhang, Yi Cui, Yongqiang Ye, Xuting Zhi, Shiping Li, Shiping Li, Guozheng Pan, Changlin Ma, Jinhua Hu, Jun Li, Suling Wang, Yuangang Qiao, Wanhua Ren, Qi Meng. Efficacy and safety of apatinib in treatment of unresectablehepatocellular carcinoma: A real-world study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5249.
Enhancing PD-L1 Degradation by ITCH during MAPK Inhibitor Therapy Suppresses Acquired Resistance
Authors: Zhentao Yang, Yan Wang, Sixue Liu, Weixian Deng, Shirley H. Lomeli, Gatien Moriceau, James Wohlschlegel, Marco Piva, Roger S. Lo
Journal: Cancer Discovery (2022)

Abstract MAPK inhibitor (MAPKi) therapy in melanoma leads to the accumulation of tumor-surface PD-L1/L2, which may evade antitumor immunity and accelerate acquired resistance. Here, we discover that the E3 ligase ITCH binds, ubiquitinates, and downregulates tumor-surface PD-L1/L2 in MAPKi-treated human melanoma cells, thereby promoting T-cell activation. During MAPKi therapy in vivo, melanoma cell–intrinsic ITCH knockdown induced tumor-surface PD-L1, reduced intratumoral cytolytic CD8+ T cells, and accelerated acquired resistance only in immune-competent mice. Conversely, tumor cell–intrinsic ITCH overexpression reduced MAPKi-elicited PD-L1 accumulation, augmented intratumoral cytolytic CD8+ T cells, and suppressed acquired resistance in BrafV600MUT, NrasMUT, or Nf1MUT melanoma and KrasMUT-driven cancers. CD8+ T-cell depletion and tumor cell–intrinsic PD-L1 overexpression nullified the phenotype of ITCH overexpression, thereby supporting an in vivo ITCH–PD-L1–T-cell regulatory axis. Moreover, we identify a small-molecular ITCH activator that suppresses acquired MAPKi resistance in vivo. Thus, MAPKi-induced PD-L1 accelerates resistance, and a PD-L1–degrading ITCH activator prolongs antitumor response. Significance: MAPKi induces tumor cell–surface PD-L1 accumulation, which promotes immune evasion and therapy resistance. ITCH degrades PD-L1, optimizing antitumor T-cell immunity. We propose degrading tumor cell–surface PD-L1 and/or activating tumor-intrinsic ITCH as strategies to overcome MAPKi resistance. This article is highlighted in the In This Issue feature, p. 1825
Abstract 3771: Mitochondrial metabolism and racial disparity of bladder cancer
Authors: Karthik Reddy Kami Reddy, Jun Hyoung Park, Roni J. Bollag, Allison Bellman, Martha Terris, Seth P. Lerner, Leomar Y. Ballester, Yair Lotan, Benny Abraham Kaipparettu, Nagireddy Putluri
Journal: Cancer Research (2022)

Abstract Potential differences and mechanism in metabolism among bladder cancer (BLCA) patients of diverse race or ethnicities remain largely unexplored. Even though the incidence rate of BLCA in African Americans (AA) is nearly half as that of European Americans (EA), but AA have the worst survival. We performed the transcriptomics and metabolomics profiling in ancestry verified patients from AA and EA BLCA and observed mitochondrial complex activities were uniquely enriched in AA tumors compared to EA tumors. In addition, in vitro assay demonstrated differences in mitochondrial complex protein and activity between AA and EA BLCA. We further confirmed the reprogramming of mitochondrial metabolism using in vitro 13C labeled tracers in both AA and EA BLCA. Integration of metabolomics and transcriptomics data reveals the enrichment of mTOR pathway in AA BLCA. Our findings indicate that an elevated mitochondrial oxphos activity through mTOR activation could be a factor for AA BLCA progression and provide the rationale to examine mitochondrial specific inhibitors along with mTOR inhibitors to target BLCA on subset of patients from the AA community. Citation Format: Karthik Reddy Kami Reddy, Jun Hyoung Park, Roni J. Bollag, Allison Bellman, Martha Terris, Seth P. Lerner, Leomar Y. Ballester, Yair Lotan, Benny Abraham Kaipparettu, Nagireddy Putluri. Mitochondrial metabolism and racial disparity of bladder cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3771.
Abstract 1486: MicroRNA (miR)199a-5p targets JUN-B to decrease cell proliferation in esophageal cancer cells
Authors: Pornima Phatak, Mohan E. Tulapurkar, James M. Donahue
Journal: Cancer Research (2022)

Abstract Objectives: MiR-199a-5p has been shown to be downregulated in multiple malignancies and function as a tumor suppressor. We have previously demonstrated that miR-199a-5p is markedly downregulated in esophageal cancer cell lines compared to esophageal epithelial cells. In several miR-target sequence analysis programs, miR-199a-5p is predicted to bind JUN-B mRNA with high affinity. JUN-B is an important component of the AP1 transcription factor. The objective of this study was to determine expression of JUN-B in esophageal cancer cells as well as to investigate the interaction between miR-199a-5p and JUNB in these cells and to characterize the functional implications of this interaction. Methods: Studies were performed in human esophageal epithelial (hESO) cells and in TE7, SK-GT-4 and OE21 human esophageal cancer cells. Expression of miR-199a-5p and JUNB mRNA in these cell lines was measured by real-time PCR. JUNB protein expression levels were examined by Western blot. Function of miR-199a-5p was tested through its overexpression and silencing. Cellular proliferation was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Results: Levels of miR-199a-5p in TE7, SK-GT-4, and OE21 esophageal cancer cells are markedly reduced compared to hESO cells. JUN-B mRNA and protein expression are correspondingly elevated in these cells compared to hESO cells. JUN-B mRNA and protein expression levels were decreased following miR-199a-5p overexpression in TE7, SK-GT-4 and OE21 cells. In reciprocal experiments, silencing miR-199a-5p in hESO cells resulted in increased JUN-B protein and mRNA levels. Forced expression of miR-199a-5p in TE7, SK-GT-4 and OE21 cells led to a marked decrease in cellular proliferation. Conclusions: MiR-199a-5p expression is significantly reduced in TE7, SK-GT-4, and OE21 esophageal cancer cells relative to hESO cells. Forced expression of miR-199a-5p results in significantly decreased JUN-B mRNA and protein expression in these cells, leading to decreased cellular proliferation. These results add our understanding of the roles by which miR-199a-5p functions as a tumor suppressor in esophageal cancer cells. Further studies will investigate the association of miR-199a-5p with JUN-B mRNA using biotinylated RNA pull-down and luciferase reporter assays, in addition to determining the effect of Jun-B downregulation on AP1 promoter activity. Citation Format: Pornima Phatak, Mohan E. Tulapurkar, James M. Donahue. MicroRNA (miR)199a-5p targets JUN-B to decrease cell proliferation in esophageal cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1486.
Abstract 299: Self-assembling nanoparticles: A novel approach for targeted cancer treatment using tumor treating fields
Authors: Preshita Prafulla Desai, Sunil Prabhu
Journal: Cancer Research (2022)

Abstract Tumor Treating Fields (TTFields) are used in cancer treatment as they offer increased efficacy, safety, and low adverse effects. They have shown significant potential in pancreatic cancer (PC) clinical trials when combined with chemotherapy. It is pertinent to know that although TTFields-chemotherapy combination definitely enhances the treatment efficacy, it also results in chemotherapy induced severe adverse effects. To resolve this, we earlier reported development of Gemcitabine loaded self-assembling cationic-anionic polymer nanoparticles (S-CAP NPs) capable of achieving TTFields-triggered targeted drug release at the PC tumor site. Initially, four S-CAP NPs [C4 and C7 from chitosan- bovine serum albumin (Chitosan-BSA) S-CAP NPs; P5 and P8 from polyethylenimine- bovine serum albumin (PEI-BSA) S-CAP NPs] were shortlisted [Table 1 - particle size: ~ 200 nm; % encapsulation efficiency (EE): 55-65%]. For proof-of-concept studies, effect of TTFields on the % EE and % cumulative drug release of the S-CAP-NPs was investigated. The studies revealed (Table 1) significant reduction (p value &amp;lt; 0.05) in the % EE of S-CAP NPs within 48h TTFields treatment, confirming that the TTFields destabilize the NPs triggering targeted drug release. Similarly, In vitro drug release studies showed significant increase (p&amp;lt; 0.01) in rate of drug release from S-Cap NPs in presence of TTFields. The cell inhibition assay confirmed the synergism in cell apoptosis wherein PEI-BSA S-CAP NPs showed higher efficacy compared to chitosan-BSA S-CAP NPs. Further, additional stability studies continued over a period of 18 months confirmed stable formulations. In vivo acute and chronic toxicity studies are underway to identify the most optimum dose of S-CAP NPs for further in vivo efficacy studies. To summarize, S-CAP-NPs present a promising avenue to achieve targeted chemotherapy in conjunction with TTFields. This work is supported by AACR-Novocure tumor treating fields research fellowship. Table 1. Effect of TTFields on % encapsulation efficiency (n=3). Data represented as Mean ± SD. Batch Particle size (nm) Encapsulation efficiency (%) - 0h Encapsulation efficiency (%) - 24h - 150 KHZ Encapsulation efficiency (%) - 48h - 150 KHZ Chitosan-BSA S-CAP NPs C4 210.54 ± 38.96 61.26 ± 5.11 36.21 ± 3.53 24.86 ± 3.19 C7 215.67 ± 32.55 65.31 ± 5.84 32.19 ± 2.68 21.86 ± 4.64 PEI-BSA S-CAP NPs P5 198.29 ± 41.05 58.83 ± 3.33 27.66 ± 3.31 18.96 ± 3.96 P8 209.92 ± 31.33 64.31 ± 5.13 24.83 ± 4.29 19.42 ± 2.73 Citation Format: Preshita Prafulla Desai, Sunil Prabhu. Self-assembling nanoparticles: A novel approach for targeted cancer treatment using tumor treating fields [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 299.
Abstract 2444: The integrin alpha10beta1 antibody TARG10 reduces tumor growth and metastasis of triple negative breast cancer
Authors: Katarzyna Masoumi, Xiaoli Huang, Anna Mirkov, Kristine Smedenfors, Per Norlén, Evy Lundgren-Åkerlund
Journal: Cancer Research (2022)

Abstract Triple negative breast cancer (TNBC) is an aggressive form of breast cancer that accounts for 10-15% of all breast cancer diagnoses. It is far more aggressive than other breast cancer types due to a higher degree of metastases and frequent relapses following current treatment options. Integrin alpha10beta1 is a collagen binding receptor that has emerged as a promising new cancer target due to its role in tumor cell proliferation and migration. The aim of the present study was to investigate the function blocking activity of the human integrin alpha10beta1 antibody TARG10 on growth and metastasis of TNBC.We have found that integrin alpha10beta1 is highly expressed in TNBC, with minimal expression in healthy tissue, and that high expression is correlated with poor prognosis in TNBC patients. In vitro studies showed significant inhibiting effects of TARG10 on the adhesion, migration, proliferation, and viability of TNBC cells. In an orthotopic xenograft TNBC model, TARG10 confirmed inhibitory effects on both tumor growth and metastasis as demonstrated by In Vivo Imaging System (IVIS-CT). The effect on metastasis was further demonstrated in a tail vein xenograft TNBC model of experimental metastasis. Pharmaceutical evaluation demonstrated excellent developability properties, including low post translational liabilities, high melting point, low aggregation and high yield.In summary, integrin alpha10beta1 represents a promising target for directed antibody-based therapy of TNBC. Our in vitro and in vivo data supports pre-clinical and clinical development of TARG10 as a candidate drug for treatment of patients with triple negative breast cancer. Citation Format: Katarzyna Masoumi, Xiaoli Huang, Anna Mirkov, Kristine Smedenfors, Per Norlén, Evy Lundgren-Åkerlund. The integrin alpha10beta1 antibody TARG10 reduces tumor growth and metastasis of triple negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2444.
European Association of Urology Guidelines on Male Urinary Incontinence
Authors: Mauro Gacci, Vasileios I. Sakalis, Markos Karavitakis, Jean-Nicolas Cornu, Christian Gratzke, Thomas R.W. Herrmann, Iason Kyriazis, Sachin Malde, Charalampos Mamoulakis, Malte Rieken, Natasha Schouten, Emma J. Smith, Mark J. Speakman, Kari A.O. Tikkinen, Stavros Gravas
Journal: European Urology (2022)